These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 8794987

  • 21. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist.
    Modesti PA, Cecioni I, Colella A, Costoli A, Paniccia R, Neri Serneri GG.
    Br J Pharmacol; 1994 May; 112(1):81-6. PubMed ID: 8032666
    [Abstract] [Full Text] [Related]

  • 22. Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis.
    Hussein Z, Samara E, Locke CS, Orchard MA, Ringham GL, Granneman GR.
    Clin Pharmacol Ther; 1994 Apr; 55(4):441-50. PubMed ID: 8162671
    [Abstract] [Full Text] [Related]

  • 23. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
    Imura Y, Terashita Z, Shibouta Y, Nishikawa K.
    Eur J Pharmacol; 1988 Mar 15; 147(3):359-65. PubMed ID: 2967770
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov 15; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

  • 27. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
    Turini ME, Holub BJ.
    Biochim Biophys Acta; 1994 Jun 23; 1213(1):21-6. PubMed ID: 8011675
    [Abstract] [Full Text] [Related]

  • 28. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans.
    Ohnishi A, Ishizaki T, Echizen H, Yasuda K, Fujiwara H, Tanaka T.
    Clin Pharmacol Ther; 1992 Apr 23; 51(4):454-64. PubMed ID: 1563215
    [Abstract] [Full Text] [Related]

  • 29. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 30. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y, Hattori R, Takatsu Y, Nakajima H, Wakabayashi A, Kawai C, Kayama N, Hiraku S, Inagawa T, Tsubojima M.
    Circulation; 1984 Oct 28; 70(4):599-605. PubMed ID: 6434196
    [Abstract] [Full Text] [Related]

  • 31. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
    Uyama O, Nagatsuka K, Nakabayashi S, Isaka Y, Yoneda S, Kimura K, Abe H.
    Stroke; 1985 Oct 28; 16(2):241-4. PubMed ID: 3883580
    [Abstract] [Full Text] [Related]

  • 32. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys.
    Schumacher WA, Steinbacher TE, Youssef S, Ogletree ML.
    Prostaglandins; 1992 Nov 28; 44(5):389-97. PubMed ID: 1301074
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 9, 11-Azo-12-oxa-15-hydroxyprostanoic acid: a potent thromboxane synthetase inhibitor and a PGH2/TxA2 receptor antagonist.
    Kam ST, Portoghese PS.
    Prostaglandins Med; 1979 Nov 28; 3(5):279-90. PubMed ID: 233035
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA, Batey AJ, Coker SJ.
    Br J Pharmacol; 1997 Jul 28; 121(5):875-82. PubMed ID: 9222543
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J, Mehta P, Lawson DL, Ostrowski N, Brigmon L.
    J Lab Clin Med; 1985 Sep 28; 106(3):246-52. PubMed ID: 3928780
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.